Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chilton, P. M.
Right arrow Articles by Ildstad, S. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chilton, P. M.
Right arrow Articles by Ildstad, S. T.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 53:1995-2002, 2004
© 2004 by the American Diabetes Association, Inc.

Flt3-Ligand Treatment Prevents Diabetes in NOD Mice

Paula M. Chilton1, Francine Rezzoug1, Isabelle Fugier-Vivier1,2, Leslie A. Weeter1,2, Hong Xu1, Yiming Huang1, Mukunda B. Ray3, and Suzanne T. Ildstad1

1 Institute for Cellular Therapeutics, University of Louisville, Louisville, Kentucky
2 Department of Physiology and Biophysics, University of Louisville, Louisville, Kentucky
3 Department of Pathology, University of Louisville, Louisville, Kentucky

The mechanism by which mixed chimerism reverses autoimmunity in type 1 diabetes has not been defined. NOD mice have a well-characterized defect in the production of myeloid progenitors that is believed to contribute significantly to the autoimmune process. We therefore investigated whether chimerism induces a correction of this defect. Mixed chimerism restored production of myeloid progenitors in NOD mice to normal levels. Notably, NOD bone marrow cells as well as donor bone marrow cells produced the mature myeloid progeny, and the level of donor chimerism was not correlated with the degree of restoration of the defect. Moreover, NOD bone marrow cells cultured with Flt3-ligand developed a heat-stable antigen-positive/Ly6C+ population comprised primarily of mature myeloid dendritic cells, suggesting that the underlying abnormality is not cell intrinsic but rather due to a block in development of mature myeloid progeny, including myeloid dendritic cells. Strikingly, treatment of NOD mice with Flt3-ligand significantly decreased insulitis and progression to diabetes and was associated with a significant increase in myeloid dendritic cells and in vivo induction of CD4+/CD25+ cells in the pancreatic lymph node. Therefore, Flt3-ligand treatment and/or the establishment of mixed chimerism in prediabetic candidates may provide a benign and novel approach to treat diabetes.


Address correspondence and reprint requests to Suzanne T. Ildstad, MD, Director, Institute for Cellular Therapeutics, the Jewish Hospital Distinguished Professor of Transplantation, University of Louisville, 570 S. Preston St., Suite 404, Louisville, KY 40202-1760. E-mail: suzanne.ildstad{at}louisville.edu


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Immunol.Home page
D. Zipris, E. Lien, A. Nair, J. X. Xie, D. L. Greiner, J. P. Mordes, and A. A. Rossini
TLR9-Signaling Pathways Are Involved in Kilham Rat Virus-Induced Autoimmune Diabetes in the Biobreeding Diabetes-Resistant Rat
J. Immunol., January 15, 2007; 178(2): 693 - 701.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
D. V. Serreze, M. A. Osborne, Y.-G. Chen, H. D. Chapman, T. Pearson, M. A. Brehm, and D. L. Greiner
Partial versus Full Allogeneic Hemopoietic Chimerization Is a Preferential Means to Inhibit Type 1 Diabetes as the Latter Induces Generalized Immunosuppression
J. Immunol., November 15, 2006; 177(10): 6675 - 6684.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
P. Schnorrer, G. M. N. Behrens, N. S. Wilson, J. L. Pooley, C. M. Smith, D. El-Sukkari, G. Davey, F. Kupresanin, M. Li, E. Maraskovsky, et al.
The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture
PNAS, July 11, 2006; 103(28): 10729 - 10734.
[Abstract] [Full Text] [PDF]


Home page
Stem CellsHome page
Y. Huang, M. Kucia, F. Rezzoug, J. Ratajczak, M. K. Tanner, M. Z. Ratajczak, C. L. Schanie, H. Xu, I. Fugier-Vivier, and S. T. Ildstad
Flt3-Ligand-Mobilized Peripheral Blood, but Not Flt3-Ligand-Expanded Bone Marrow, Facilitating Cells Promote Establishment of Chimerism and Tolerance
Stem Cells, April 1, 2006; 24(4): 936 - 948.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
G. F. Beilhack, R. R. Landa, M. A. Masek, and J. A. Shizuru
Prevention of Type 1 Diabetes with Major Histocompatibility Complex-Compatible and Nonmarrow Ablative Hematopoietic Stem Cell Transplants
Diabetes, June 1, 2005; 54(6): 1770 - 1779.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. T. Ildstad, P. M. Chilton, H. Xu, M. A. Domenick, and M. B. Ray
Preconditioning of NOD mice with anti-CD8 mAb and costimulatory blockade enhances chimerism and tolerance and prevents diabetes, while depletion of {alpha}{beta}-TCR+ and CD4+ cells negates the effect
Blood, March 15, 2005; 105(6): 2577 - 2584.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
M. O'Keeffe, T. C. Brodnicki, B. Fancke, D. Vremec, G. Morahan, E. Maraskovsky, R. Steptoe, L. C. Harrison, and K. Shortman
Fms-like tyrosine kinase 3 ligand administration overcomes a genetically determined dendritic cell deficiency in NOD mice and protects against diabetes development
Int. Immunol., March 1, 2005; 17(3): 307 - 314.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2004 by the American Diabetes Association.